Author

O. Heidenreich

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 6

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Organism:human· 5 Assay:bulk RNA-seq· 3 Research Focus:cancer & tumor microenvironment· 3 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Research Focus:cell type annotation· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

H. Blair· 4 shared S. Nakjang· 3 shared A. Krippner-Heidenreich· 2 shared C. Bonifer· 2 shared A. Adamo· 1 shared A. Filby· 1 shared A. Fuller· 1 shared A. Isa· 1 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

H. Blair

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

The neuronal homeobox transcription factor HMX3 is a crucial vulnerability factor in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia

S. Arza-Apalategi, B. M. H. Heuts, S. M. Bergevoet, R. Meering, D. Gilissen, P. W. T. C. Jansen, A. Krippner-Heidenreich, P. J. M. Valk, M. Vermeulen, O. Heidenreich, T. Haferlach, J. H. Jansen, J. H. A. Martens, B. A. van der Reijden

The paper identifies HMX3 as a critical vulnerability in MECOM-negative KMT2A::MLLT3 AML, showing it promotes proliferation and blocks differentiation.

bioRxiv · Nov 7, 2023 · PreprintCancer Biology

Leukemic stem cells hijack lineage inappropriate signalling pathways to promote their growth

S. G. Kellaway, S. Potluri, P. Keane, H. Blair, P. S. Chin, A. Ptasinska, A. Worker, L. Ames, A. Adamo, D. J. Coleman, N. Khan, S. Assi, A. Krippner-Heidenreich, M. Raghavan, P. N. Cockerill, , C. Bonifer

This study identifies VEGF and IL-5 signalling pathways as aberrantly activated in t(8;21) leukemic stem cells, enabling their growth and relapse.

bioRxiv · Mar 10, 2023Cancer Biology

Nanoparticle-mediated Targeting of the Fusion Gene RUNX1/ETO in t(8;21)-positive Acute Myeloid Leukaemia

H. Issa, L. Swart, M. Rasouli, M. Ashtiani, S. Nakjang, n. jyotsana, K. Schuschel, M. Heuser, H. Blair, O. Heidenreich

This study uses siRNA-loaded lipid nanoparticles to target the RUNX1/ETO fusion gene in t(8;21)-AML, showing improved survival and long-term inhibition of leukaemic growth.

bioRxiv · Sep 21, 2022Cancer Biology

An ex vivo human bone marrow milieu identifies CDH2 as a driver of niche-mediated treatment resistance in leukaemia

D. Pal, H. Blair, S. Boyd, S. Angel, S. Nizami, A. Isa, M. Beckett, R. Nelson, A. Wilson, M. Singh, S. Sankar, R. Tirtakusuma, S. Nakjang, C. Knill, A. Fuller, , J. Vormoor

This study identifies CDH2 as a driver of niche-mediated treatment resistance in leukemia and shows that ADH-1 can effectively target this resistance in preclinical models.

bioRxiv · Jun 18, 2021Cancer Biology

A MALDI-TOF assay identifies nilotinib as an inhibitor of inflammation in acute myeloid leukaemia

J. L. Marin-Rubio, R. E. Heap, T. Heunis, M. E. Duenas, J. Inns, J. Scott, A. J. Simpson, J. M. Allan, H. Blair, O. Heidenreich, B. Saxty, M. Trost

This study identifies nilotinib as an anti-inflammatory drug using a MALDI-TOF assay in AML-derived monocytes, showing it inhibits the p38-MK2/3 signaling axis.

bioRxiv · Mar 29, 2021 · PreprintCancer Biology

RUNX1/RUNX1T1 controls alternative splicing in the t(8;21)-positive acute myeloid leukemia cells

V. Grinev, I. Ilyushonak, R. Clough, S. Nakjang, J. Smink, N. Martinez-Soria, T. Ramanouskaya, C. Bonifer, O. Heidenreich

This study identifies two mechanisms by which RUNX1/RUNX1T1 regulates alternative splicing in t(8;21)-positive acute myeloid leukemia cells, affecting RNA isoform production and protein structure.

bioRxiv · May 4, 2019 · PreprintCancer Biology